Jazz Pharmaceuticals PLC: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Jazz Pharmaceuticals PLC Unternehmen

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Jazz Pharmaceuticals PLC Informationen



BörsenkürzelJAZZ

Name des UnternehmensJazz Pharmaceuticals PLC

IPO-datumJan 18, 2012

CEOGala (Renee D)

Anzahl der mitarbeiter2800

WertpapierartOrdinary Share

GeschäftsjahresendeJan 18

AddresseFifth Floor, Waterloo Exchange

StadtDUBLIN

BörseNASDAQ OMX - NASDAQ BASIC

LandIreland

Postleitzahl- -

Telefon35316347800

Websitehttps://www.jazzpharma.com/

BörsenkürzelJAZZ

IPO-datumJan 18, 2012

CEOGala (Renee D)

Führungskräfte von Jazz Pharmaceuticals PLC



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.02%

Mr. Bruce C. Cozadd

Chairman of the Board

337.29K

-1.78%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

46.93K

-97.93%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

40.33K

+0.08%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

20.53K

-18.10%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

20.05K

-38.09%

Ms. Samantha Pearce

Executive Vice President, Chief Commercial Officer

17.01K

-9.11%

Ms. Anne O'Riordan

Independent Director

12.99K

+1.72%

Dr. Norbert G. Riedel, Ph.D.

Independent Director

12.36K

-12.66%

Ms. Jennifer E. Cook

Independent Director

7.33K

+3.06%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Seamus C. Mulligan

Independent Director

1.28M

+0.02%

Mr. Bruce C. Cozadd

Chairman of the Board

337.29K

-1.78%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

46.93K

-97.93%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

40.33K

+0.08%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

20.53K

-18.10%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

20.05K

-38.09%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Xywav

1.66B

38.83%

Epidiolex/epidyolex

1.06B

24.82%

Rylaze

402.92M

9.44%

Zepzelca

307.31M

7.20%

High-sodium oxybate AG royalty revenue

211.72M

4.96%

Andere

629.45M

14.75%

Nach RegionUSD

Name

Umsatz

Anteil

United States

3.83B

89.78%

Europe

341.12M

7.99%

All Others

94.87M

2.22%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Xywav

1.66B

38.83%

Epidiolex/epidyolex

1.06B

24.82%

Rylaze

402.92M

9.44%

Zepzelca

307.31M

7.20%

High-sodium oxybate AG royalty revenue

211.72M

4.96%

Andere

629.45M

14.75%

Aktionärsstatistik

Aktualisiert: 6 hours ago

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

7.91%

Vanguard Portfolio Management, LLC

4.75%

Capital World Investors

4.25%

Vanguard Capital Management, LLC

4.22%

LSV Asset Management

3.91%

Andere

74.95%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

7.91%

Vanguard Portfolio Management, LLC

4.75%

Capital World Investors

4.25%

Vanguard Capital Management, LLC

4.22%

LSV Asset Management

3.91%

Andere

74.95%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

59.87%

Investment Advisor/Hedge Fund

32.31%

Hedge Fund

12.09%

Individual Investor

3.04%

Research Firm

2.90%

Venture Capital

1.86%

Pension Fund

1.62%

Bank and Trust

1.04%

Private Equity

0.27%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

1229

70.31M

112.06%

-754.07K

2025Q4

1201

62.79M

103.33%

-9.05M

2025Q3

1197

64.03M

105.38%

-5.21M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

4.96M

8.06%

-50.61K

-1.01%

Dec 31, 2025

Capital World Investors

2.67M

4.33%

+111.73K

+4.37%

Dec 31, 2025

LSV Asset Management

2.46M

3.99%

-55.90K

-2.23%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

2.62M

4.26%

-213.35K

-7.52%

Dec 31, 2025

State Street Investment Management (US)

1.84M

2.99%

-30.09K

-1.61%

Dec 31, 2025

Franklin Advisers, Inc.

1.81M

2.95%

+1.13M

+164.20%

Dec 31, 2025

EcoR1 Capital, LLC

1.71M

2.77%

--

Dec 31, 2025

Fuller & Thaler Asset Management Inc.

1.68M

2.72%

+51.00K

+3.14%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Cambria Cannabis ETF

4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

3.11%

iShares U.S. Pharmaceuticals ETF

3.08%

Invesco Pharmaceuticals ETF

2.94%

State Street SPDR S&P Pharmaceuticals ETF

2.83%

Abacus FCF International Leaders ETF

2.69%

First Trust NASDAQ Pharmaceuticals ETF

2.51%

Clough Hedged Equity ETF

2.4%

Alger Russell Innovation ETF

2.12%

VictoryShares Small Cap Free Cash Flow ETF

1.77%

Cambria Cannabis ETF

Anteil4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Anteil3.11%

iShares U.S. Pharmaceuticals ETF

Anteil3.08%

Invesco Pharmaceuticals ETF

Anteil2.94%

State Street SPDR S&P Pharmaceuticals ETF

Anteil2.83%

Abacus FCF International Leaders ETF

Anteil2.69%

First Trust NASDAQ Pharmaceuticals ETF

Anteil2.51%

Clough Hedged Equity ETF

Anteil2.4%

Alger Russell Innovation ETF

Anteil2.12%

VictoryShares Small Cap Free Cash Flow ETF

Anteil1.77%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten